Novel Approaches for Improving Vascular Function in Veterans With HFpEF

Description

This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF).

Conditions

HFpEF - Heart Failure With Preserved Ejection Fraction, Inflammation

Talk to us

Study Overview

On this page

Study Details

Study overview

This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF).

Novel Approaches for Improving Vascular Function in Veterans With HFpEF

Novel Approaches for Improving Vascular Function in Veterans With HFpEF

Condition
HFpEF - Heart Failure With Preserved Ejection Fraction
Intervention / Treatment

-

Contacts and Locations

Salt Lake City

George E. Whalen VA Medical Center, Salt Lake City, Utah, United States, 84128

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18 years or older and able to give written informed consent.
  • * New York Heart Association (NYHA) functional class I, II, or III.
  • * Left Ventricular Ejection Fraction (LVEF) \> 50%.
  • * Plasma Brain Natriuretic Peptide (BNP) ≥150 pg/mL or NT-proBNP ≥600 pg/mL at Visit 1, or a BNP ≥100 pg/mL (or NT-proBNP ≥400 pg/mL) and a hospitalization for heart failure within the last 12 months.
  • * History of hypersensitivity or allergy to any lipophilic statin.
  • * Prior EF \<50%.
  • * NYHA Class IV.
  • * Patients with HFpEF secondary to significant uncorrected primary valvular disease.
  • * Active liver disease or unexplained persistent elevations in serum transaminase.
  • * Women who are pregnant or may become pregnant.
  • * Patients currently treated with antioxidants, nitrates, PDE-5 inhibitors, or statins.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

D. Walter Wray,

Study Record Dates

2030-09-30